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were analyzed to retrospectively determine visceral adipose 
tissue area  (cm2); intermuscular adipose tissue area  (cm2) 
and mean muscle attenuation (Hounsfield units) as meas-
ures of muscle fat infiltration; and skeletal muscle index 
(SMI,  cm2/m2) as measure of muscle mass and for deter-
mining sarcopenia.
Results Participants showed a large variation in body 
composition parameters at CRC diagnosis with a mean 
visceral adipose tissue area of 136.1 cm2 (standard devia-
tion: 93.4) and SMI of 47.8  cm2/m2 (7.2); 47% was clas-
sified as being viscerally obese, and 32% as sarcopenic. In 
multivariable linear regression models, associations of the 
body composition parameters with long-term global qual-
ity of life, physical, role and social functioning, disability, 
fatigue, and distress were not significant, and observed 
mean differences were below predefined minimal important 
differences.
Conclusions Although visceral obesity and sarcopenia 
are relatively common at CRC diagnosis, we found no sig-
nificant associations of these parameters with long-term 
HRQoL in stage I–III CRC survivors.
Keywords Visceral adiposity · Muscle wasting · 
Sarcopenia · Health-related quality of life · Colorectal 
cancer
Introduction
Globally, over 3.5  million individuals are living with a 
diagnosis of CRC in the past 5 years [1]. CRC patients 
often suffer from adverse effects of their disease and its 
treatment, leading to problems such as fatigue, bowel dys-
function, and distress [2–4]. These problems frequently 
persist for more than 5 years post-treatment and can 
Abstract 
Purpose Increased visceral adiposity (visceral obesity) 
and muscle wasting (sarcopenia) at colorectal cancer (CRC) 
diagnosis, quantified by computed tomography (CT) image 
analysis, have been unfavorably associated with short-term 
clinical outcomes and survival, but associations with long-
term health-related quality of life (HRQoL) have not been 
investigated. We studied associations of visceral adiposity, 
muscle fat infiltration, muscle mass, and sarcopenia at CRC 
diagnosis with HRQoL 2–10 years post-diagnosis.
Methods A cross-sectional study was conducted in 104 
stage I‒III CRC survivors, diagnosed at Maastricht Univer-
sity Medical Center+, the Netherlands (2002–2010). Diag-
nostic CT images at the level of the third lumbar vertebra 
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severely impact the health-related quality of life (HRQoL) 
of CRC survivors in the long term [5]. Since the popula-
tion of CRC survivors is steadily growing [6], it is a major 
research priority to identify characteristics of CRC patients 
with an increased risk of low long-term HRQoL [7], for 
this could enable development of  targeted interventions 
to prevent HRQoL deterioration. In a recent systematic 
review, a comprehensive overview was provided on biopsy-
chosocial factors associated with HRQoL of CRC survi-
vors [8]. Strong evidence for an association with a lower 
HRQoL was found for several factors potentially associated 
with a more unfavorable body composition, including the 
presence of comorbidity, fatigue, and psychological dis-
tress, low levels of physical activity, low socioeconomic 
status, and shorter time since CRC diagnosis. The evidence 
was graded inconsistent for gender and cancer stage. In 
addition, a strong level of evidence was found for obesity 
being associated with worse HRQoL outcomes in CRC 
survivors. Indeed, previous prospective and cross-sectional 
studies have found that a higher body mass index (BMI) or 
the presence of obesity in comparison to other BMI cat-
egories in the period from 6 months until 10 years after 
CRC diagnosis was associated with a lower HRQoL in 
CRC survivors, in particular with a lower level of physical 
functioning [9–14]. Thus, specific characteristics of body 
composition of CRC patients at diagnosis (i.e., distribution 
and amount of adipose and muscle tissue) are likely to be 
associated with their health status, and therefore possibly 
also with long-term HRQoL in the post-diagnosis period. 
As increased adiposity is an established risk factor for CRC 
development [15], and muscle wasting can be an important 
consequence of cancer [16], a relatively high prevalence of 
these unhealthy body composition profiles can be expected 
in CRC patients at diagnosis.
Detailed and accurate body composition analysis of 
muscle tissue and different adipose tissue compartments at 
CRC diagnosis is possible through the use of images from 
routinely taken diagnostic computed tomography (CT) 
scans [17]. CT-based body composition analysis enables a 
highly accurate and precise quantification of muscle mass 
and different types of adipose tissue, which is to be pre-
ferred over more crude and inaccurate measures of body 
composition such as BMI [18]. As these CT scans are made 
as part of standard diagnostic procedures of cancer patients 
and therefore readily available for the majority of patients 
at the moment of diagnosis, this provides the opportunity to 
determine these parameters that are likely associated with 
long-term health outcomes. Previous research using CT-
derived body composition parameters has observed associ-
ations of increased visceral adiposity (visceral obesity) and 
excessive muscle wasting (sarcopenia) at CRC diagnosis 
with worse short-term clinical outcomes and survival [19]. 
In particular, increased visceral adipose tissue has been 
associated with a higher rate of postoperative infections 
and/or complications [20–22], a longer postoperative hospi-
tal stay [20], and poorer disease-free survival [21, 23, 24]. 
In addition, parameters of skeletal muscle wasting (sarco-
penia) have been associated with a longer length of hospital 
stay [25], more postoperative infections and/or complica-
tions [25, 26], increased chemotherapy toxicity [27], higher 
30-day mortality [28], and worse recurrence-free [29] and 
overall survival [29–31]. Specifically, these studies found 
adverse effects of both reduced skeletal muscle mass [25, 
27–31], and increased fat infiltration within muscle tissue 
(i.e., attenuation) [26, 31], which is an indicator of muscle 
quality and function [32, 33].
The above thus suggests that visceral adiposity and mus-
cle wasting at CRC diagnosis can have negative effects on 
the frequency of postoperative complications and survival. 
However, whether these body composition parameters 
are also important for long-term HRQoL (≥2 years post-
diagnosis) has not been investigated yet. As the occurrence 
of postoperative complications in CRC patients has been 
associated with worse global HRQoL [34], lower physical 
HRQoL, and more fatigue [35], 1–4 years post-diagnosis, 
it can be hypothesized that unfavorable muscle and adipose 
tissue parameters at CRC diagnosis are associated with 
long-term HRQoL. Further, sarcopenia at cancer diagnosis 
is an important factor associated with the development of 
cancer-related fatigue [36], and for this reason it can also 
be expected to negatively influence long-term quality of life 
in cancer patients [37]. In a small study in 50 stage IV CRC 
survivors, it has been found that sarcopenia at the moment 
of chemotherapy referral, determined by CT image analy-
sis, was negatively associated with physical functioning, 
but not with other HRQoL outcomes [38]. However, this 
was a cross-sectional study with measures taken after diag-
nosis and in a select group of only stage IV CRC patients. 
In the light of future intervention programs aiming to pre-
vent HRQoL deterioration in CRC survivors, it is of par-
ticular importance to study the associations of these body 
composition features at diagnosis in relation to long-term 
HRQoL. This would allow the development of interven-
tions that can be provided at an early stage (e.g., nutritional 
support and exercise training before colorectal surgery to 
improve nutritional and functional status [39, 40]) and spe-
cifically targeted towards those CRC survivors in need of 
additional care. Thus, more research is necessary to deter-
mine whether parameters of visceral obesity and muscle 
wasting at CRC diagnosis are associated with long-term 
HRQoL outcomes in CRC survivors.
Therefore, our objective was to study associations of 
body composition parameters at CRC diagnosis with long-
term HRQoL in CRC survivors, 2–10 years post-diagnosis. 
Specifically, we determined visceral adiposity, muscle fat 
infiltration, muscle mass, and sarcopenia through CT image 
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analysis. We hypothesized that increased visceral adipos-
ity and muscle fat infiltration, lower muscle mass, and sar-




Data from the cross-sectional part of the Energy for life 
after ColoRectal cancer (EnCoRe) study were used. Meth-
ods of the EnCoRe study have been described in detail else-
where [41]. The cross-sectional part of the EnCoRe study 
was conducted in CRC survivors recruited 2–10 years 
post-diagnosis. Eligible individuals, i.e., persons diag-
nosed with and treated for stage I–III CRC between 2002 
and 2010 at Maastricht University Medical Center+, the 
Netherlands, were preselected via the Netherlands Can-
cer Registry (managed by Comprehensive Cancer Centre 
the Netherlands). The main aim of the EnCoRe study is to 
investigate the associations of lifestyle factors with HRQoL 
in CRC survivors. Patients with stage IV CRC were there-
fore not included, since we hypothesized that their poor 
prognosis, and not lifestyle behavior, likely determines 
their HRQoL to the largest extent [41]. Participants were 
recruited between May 2012 and December 2013. Reasons 
for exclusion are shown in Fig. 1. The EnCoRe study had 
been approved by the Medical Ethics Committee of the 
Academic Hospital Maastricht and Maastricht University, 
the Netherlands. Written informed consent was obtained 
from all participants. No incentives were provided to 
participants.
Data collection
When designing the EnCoRe study, a conceptual model 
was developed for studying HRQoL in CRC survivors 
[41], based on the International Classification of Func-
tioning, Disability and Health (ICF) of the World Health 
Organization [42]. The ICF adopts a broad biopsychosocial 
definition of human functioning, including physical health 
components (body perspective) and the ability to perform 
daily activities and societal roles (individual and societal 
perspectives) [43]. Additionally, it enables the identifica-
tion of environmental and personal factors and the presence 
of health conditions that can influence functioning. The 
developed conceptual model [41] was adapted for the cur-
rent research questions to identify relevant variables to be 
included in data analyses (Online Resource 1, Supplemen-
tary Fig. 1).
Body composition variables
CT scans routinely taken at CRC diagnosis for diagnostic 
and staging purposes were obtained from medical records 
and used to quantify adipose and muscle tissue parameters 
(Fig. 2) [17, 31, 32]. CT scans taken more than 3 months 
after start of initial treatment were excluded (Fig.  1), as 
these were deemed to be unrepresentative of body compo-
sition at CRC diagnosis. The majority of included CT scans 
were taken before start of initial treatment (93%; range 
0–185 days before start of treatment; 7% post-treatment; 
4–36 days after start of treatment). According to published 
standard procedures [17, 31], the CT image at the level of 
the third lumbar vertebra (L3) was selected and analyzed 
with Slice-O-Matic software (version 5.0, TomoVision, 
Canada). It has been shown previously that cross-sectional 
areas of muscle and visceral fat tissue at a single cross-sec-
tional image at the level of L3 correlate highly with total 
body muscle mass (Pearson’s r = 0.92) [44] and visceral fat 
volume (0.95 in men, 0.94 in women) [45], respectively. 
Relevant tissues were identified based on their anatomical 
features and the level of radiodensity in Hounsfield units 
(HU). The following HU ranges were applied: visceral adi-
pose tissue, −150 to −50 HU; subcutaneous adipose tissue, 
−190 to −30 HU; intermuscular adipose tissue, −190 to 
−30 HU; and skeletal muscle, −29 to +150 HU [17]. The 
total cross-sectional area of visceral and intermuscular adi-
pose tissue, and skeletal muscle was determined  (cm2). The 
area of subcutaneous adipose tissue was not included in the 
analyses as this tissue was not fully visible (i.e., cutoff) in 
a substantial proportion of CT images (27%). CT image 
analyses were performed by two trained raters (MtM, MB). 
Intra-rater analyses showed excellent reproducibility for 
quantifying muscle and adipose tissues (absolute agree-
ment type intraclass correlations: 1.00 for 9% duplicate 
analyses).
Based on visceral adipose tissue area, participants 
were classified as viscerally obese according to published 
gender-specific cutoff values for CT images at the level 
of L3–L4 (≥160 cm2 in men; ≥80 cm2 in women) [46]. 
In addition, the skeletal muscle index (SMI) was calcu-
lated by normalizing the total area of skeletal muscle 
for height squared  (cm2/m2), as is conventional for this 
parameter [17, 31]. The SMI was used to determine the 
presence of sarcopenia, based on previously published 
threshold values for CT images at the level of L3 [31] and 
using self-reported weight at CRC diagnosis to retrospec-
tively calculate BMI at diagnosis: <41 cm2/m2 in women 
(any BMI); <43 cm2/m2 in men with a BMI <25 kg/m2; 
and <53  cm2/m2 in men with a BMI ≥25  kg/m2. Fur-
ther, mean muscle attenuation was determined as the 
mean radiodensity in HU of total skeletal muscle area. 
Next to intermuscular adipose tissue, the mean muscle 
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attenuation is a measure of muscle fat infiltration and 
quality, with lower muscle attenuation indicating more 
muscle fat infiltration [31, 32].
At the time of HRQoL assessment, 2–10 years post-
diagnosis, body height and weight were measured by 
trained personnel for calculation of BMI. In addition, as a 
measure of muscle function, isometric handgrip strength 
(kg) of the dominant hand was measured with a Jamar hand 
dynamometer (Sammons Preston Rolyan, USA), which 
has an excellent validity for measuring muscle strength in 
comparison with known weights (r > 0.99 [47]). The high-
est value of two measurements was used as a measure of 
maximum handgrip strength [48].
HRQoL outcomes
HRQoL outcomes were measured by self-report, 2–10 
years post-diagnosis. Cancer-specific HRQoL was meas-
ured using the valid and reliable European Organization 
for the Research and Treatment of Cancer Quality of Life 
Questionnaire-Core 30 (EORTC QLQ-C30, version 3.0) 
[49, 50]. For the subscales global quality of life (2 items on 
a 7-point ordinal scale ranging from ‘Very poor’ to ‘Excel-
lent’), and physical, role and social functioning (5, 2, and 2 
items, respectively, all with a 5-point ordinal scale ranging 
from ‘Not at all’ to ‘Very much’), 100-point scores were 
calculated with higher scores indicating better HRQoL 
Fig. 1  Flow diagram of 
inclusion of individuals into 
the cross-sectional part of the 
EnCoRe study and analyses pre-
sented in this paper. aReasons 
for non-eligibility are given in 
order of exclusion, totals do not 
add up because some exclusion 
criteria applied concurrently. 
bTotals do not add up because 
some individuals reported 
multiple reasons for non-partici-
pation. cThree computed tomog-
raphy (CT) images excluded 
because skeletal muscle was not 
fully visible on CT image
Men and women (≥18 years), with a history of stage I, II or 
III colorectal cancer, including recurrent colorectal cancer 
treated at Maastricht University Medical Center+ between 
2002-2010 (n = 772)
Eligible individuals were invited to participate (n = 373)
Non-eligibility (n = 399)a:
- Records of subsequent tumours of individuals 
with multiple tumours in 2002-2010 (n = 27)
- Not alive (n = 244)
- Home address outside of the Netherlands (n = 3)
- Stage IV tumour (n = 3)
- In situ tumour/no carcinoma (n = 64)
- Excluded histological subtypes: 
carcinoid/neuroendocrine tumour (n = 12) 
- Presence of co-morbidities that may obstruct 
successful participation, such as Alzheimer 
disease or severe hearing disorders (n = 27)
- Not asked due to ethical reasons, e.g. because 
of terminal illness (n = 13)
- Inability to understand the Dutch language in 
speech and writing (n = 5)
- Treatment received at other hospital (n = 2)
- Unwillingness to participate in research in 
general (n = 1)
Individuals recruited into study (n = 155, 42%)
Non-participation (n = 218, 58%)b:
- Personal circumstances (n = 101)
- Emotionally too burdensome (n = 29)
- Takes too much time (n = 15)
- No reason given (n = 39)
- Other (n = 15)
- No response, could not be contacted (n = 25)
Data available for analyses of visceral adipose tissue (n = 104, 67%)
Data available for analyses of intermuscular adipose tissue, mean 
muscle attenuation and skeletal muscle index (n = 101, 65%)c
Not included in current analyses (n = 51, 33%):
- No CT image available (n = 47)
- CT image was of insufficient quality (n = 2)
- CT scan taken more than 3 months after start of 
initial treatment (n = 2)
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[51]. These subscales have been observed to have an 
acceptable internal consistency (Cronbach’s α > 0.70) [49, 
52–55] and test–retest reliability (Pearson’s r: 0.58–0.75) 
[54]. Disability was assessed by the 12-item version of the 
ICF-based World Health Organization Disability Assess-
ment Schedule II (WHODAS II; all items with a 5-point 
ordinal scale ranging from ‘None’ to ‘Extreme or cannot 
do’) [56], which has good test–retest reliability [intraclass 
correlation coefficient (ICC) = 0.98], internal consistency 
(Cronbach’s α = 0.98), and validity in different populations, 
including cancer survivors [57, 58]. Fatigue was assessed 
through the 20-item Checklist Individual Strength (CIS; 
all items with a 7-point ordinal scale ranging from ‘Yes, 
that is true’ to ‘No, that is not true’), which was origi-
nally developed and validated in chronic fatigue syndrome 
patients [59, 60], but has also been applied in cancer survi-
vors [61]. The CIS has a good internal consistency (Cron-
bach’s α = 0.98) [59] and test–retest reliability (ICC = 0.81) 
[62]. The 14-item Hospital Anxiety and Depression Scale 
(HADS; all items with a 4-point ordinal scale with differ-
ent answer options per item) was used to determine levels 
of distress (anxiety and/or depression) [63], which has ade-
quate psychometric properties in cancer patients, includ-
ing an adequate internal consistency type of reliability 
(Cronbach’s α > 0.80) [64]. Composite scores for disability 
(0–100) [57], fatigue (20–140), and distress (0–42) [64] 
were calculated, with higher scores indicating higher levels 
of disability, fatigue, and distress, respectively.
Other factors
Socio-demographic and clinical characteristics (gender, 
age at diagnosis, cancer stage, treatment, and tumor sub-
site) were collected through the Netherlands Cancer Reg-
istry. Education level was self-reported and the number of 
comorbidities, at HRQoL assessment, was assessed using 
the Self-Administered Comorbidity Questionnaire [65].
a b
c d
Fig. 2  Computed tomography (CT) images showing the measure-
ment of skeletal muscle and different types of adipose tissue at the 
level of the third lumbar vertebra (L3); a and b show the original and 
tagged (i.e., colored) CT images, respectively, of one included CRC 
survivor [man, 50 years old at CRC diagnosis, self-reported body 
mass index (BMI) at diagnosis: 27.6  kg/m2] with a relatively high 
skeletal muscle index (67.0  cm2/m2); area of visceral adipose tissue 
and intermuscular adipose tissue: 118.3 and 10.1  cm2, respectively; 
mean muscle attenuation: 35.9 Hounsfield units (HU); c and d show 
the original and tagged CT images, respectively, of one included CRC 
survivor (woman, 49 years old at CRC diagnosis, BMI at diagnosis: 
21.0) with a relatively low skeletal muscle index (30.8 cm2/m2); area 
of visceral adipose tissue and intermuscular adipose tissue: 52.9 and 
20.4  cm2, respectively; mean muscle attenuation: 27.2 HU. Within 
the tagged figure, yellow represents visceral adipose tissue; blue rep-
resents subcutaneous adipose tissue; green represents intermuscu-
lar adipose tissue; and red represents skeletal muscle. (Color figure 
online)
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Statistical analyses
Descriptive statistics for socio-demographic and clini-
cal variables were calculated and compared between par-
ticipants included in the analyses, participants without 
CT image data, and non-participants. Further, descriptive 
statistics of body composition and HRQoL variables were 
calculated by gender. Multivariable linear regression analy-
ses were performed to determine mean differences (MDs) 
with 95% confidence intervals (CIs) in HRQoL outcomes 
between tertiles of CT-derived body composition variables 
using the first tertile as reference category. Total area of 
visceral and intermuscular adipose tissue and SMI were 
categorized into gender-specific tertiles. Tertiles of muscle 
attenuation were not gender-specific, as mean muscle atten-
uation did not differ between men and women (independent 
t test: P = 0.26). Testing for a linear trend was performed by 
including these variables as ordinal variables in the model. 
In addition, these parameters were included as continuous 
variables divided by their standard deviation (SD) in the 
study population, to calculate mean differences (MDs) in 
HRQoL scores per SD increase. Further, the dichotomous 
variables for the presence of visceral obesity and sarcope-
nia at CRC diagnosis were included to determine associa-
tions with HRQoL. Covariates included as potential con-
founding factors were selected a priori from our conceptual 
ICF model (Online Resource 1, Supplementary Fig.  1), 
comprising age at diagnosis, gender, number of comor-
bidities, cancer stage, chemotherapy treatment, and BMI 
at HRQoL assessment [the latter as proxy for self-reported 
BMI at diagnosis, because this variable was missing in 19% 
of participants and correlated highly with BMI at HRQoL 
assessment (r = 0.83)]. Based on regression diagnostics, 
the homoscedasticity assumption was not violated [66] and 
there was no multicollinearity as indicated by inspecting 
variance inflation factors [67]. Minimal important differ-
ences for all HRQoL outcomes were defined and based on 
published “medium” differences for the EORTC subscales 
[68], and 0.5 times the SD of the score for other outcomes 
[69] (disability, fatigue, and distress).
As additional analyses, we investigated associations 
of the CT-derived body composition parameters at CRC 
diagnosis with maximum handgrip strength at HRQoL 
assessment, as an objective measure of muscle strength 
and function [48]. Further, we performed stratified analy-
ses by gender to compare results between men and women. 
To avoid over-interpretation of possible chance findings, 
results of these stratified analyses were reported only if a 
significant and meaningful (i.e., larger than the minimal 
important difference) association with multiple HRQoL 
outcomes between the highest or middle versus lowest 
tertile of the body composition parameter, or between the 
two groups of the dichotomous variables (visceral obesity, 
sarcopenia) was observed in men, but not in women, or 
vice versa. Analyses were performed using IBM SPSS 
Statistics (Version 22, IBM Corporation, United States of 




In total, 373 eligible CRC survivors were invited to partici-
pate and 155 were recruited (response rate: 42%; Fig.  1). 
A total of 51 participants (33%) were excluded from the 
current analyses for having no CT image at CRC diagno-
sis (n = 47), or a CT image of insufficient quality or taken 
more than 3 months after start of treatment (both n = 2). 
Three participants were further excluded from the analy-
ses of muscle tissue parameters, due to skeletal muscle 
being not fully visible on the CT image. Non-participants 
had a higher mean age at diagnosis (67.8 years) than par-
ticipating CRC survivors included in the analyses (64.3) 
and those without CT image data (64.6; Table 1). Further, 
compared to included survivors and non-participants, CRC 
survivors without CT image data had a higher time since 
diagnosis (differences: 1.5 and 1.0 years, respectively) 
and less often colon cancer and stage III CRC (differences 
>10%). In addition, included CRC survivors without CT 
image data were less often treated with chemotherapy, and 
reported less often a lower education level and more often 
≥2 comorbidities than survivors included in the analyses 
(differences >10%).
Included survivors (n = 104, 60% men, Table 1) were on 
average 64.3 years old (SD 9.0) at CRC diagnosis and their 
mean time since diagnosis was 5.2 years (SD 1.7) at the 
time of HRQoL assessment. The majority had a history of 
colon cancer (58%), whilst 40 and 2% had a rectum and rec-
tosigmoid tumor, respectively. Nearly half (45%) reported 
having ≥2 comorbidities, and 49% were overweight (BMI 
25–30 kg/m2) and 25% obese (BMI ≥30 kg/m2) at the time 
of HRQoL assessment. According to self-reported weight 
at CRC diagnosis, 43 and 12% could be classified as over-
weight and obese, respectively.
Data derived from CT images showed a large vari-
ation in body composition parameters at CRC diagno-
sis (Table  2), with a mean visceral adipose tissue area of 
136.1 cm2 (SD 93.4), intermuscular adipose tissue area of 
14.0  cm2 (8.8), muscle attenuation of 37.1 HU (8.7), and 
SMI of 47.8  cm2/m2 (7.2). Visceral adipose tissue area 
and SMI were on average higher in men, whilst intermus-
cular adipose tissue area was higher in women, and mean 
muscle attenuation was similar between genders. BMI at 
CRC diagnosis had a low to moderate correlation with the 
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CT-derived parameters of body composition (Pearson’s r, 
ranging from −0.25 to 0.57). Based on published threshold 
values for visceral adipose tissue area [46], 49 survivors 
(47%) were classified as viscerally obese at CRC diagno-
sis (45% in men; 50% in women). In addition, using pub-
lished SMI cutoff values [31], 29 participants (32%) were 
classified as sarcopenic (28% in men; 37% in women; data 
missing for 9 men due to unknown BMI at CRC diagno-
sis). In total, 12 participants (13%) were classified as being 
both viscerally obese and sarcopenic (16% in men; 10% in 
women).
Survivors with stage III CRC reported on average a bet-
ter global quality of life, and less disability, fatigue, and 
distress than survivors with stage I/II CRC, but the differ-
ences were generally small. The other HRQoL outcomes 
scores were similar between tumor stages.
Associations of adipose and muscle tissue parameters 
with HRQoL and handgrip strength
In multivariable linear regression models, no significant 
associations were observed of all CT-derived adipose and 
muscle tissue parameters with any of the self-reported 
HRQoL outcomes (all P values for testing the significance 
of all body composition variables included as independent 
variables in linear regression models ≥0.05; Table 3). Both 
models with body composition variables in tertiles and 
as continuous variables showed non-significant findings, 
indicating no linear or non-linear statistically significant 
associations were present. In addition, observed MDs were 
smaller than predefined minimal important differences for 
the HRQoL outcomes. Similarly, no significant associa-
tions were found of the body composition parameters with 
maximum handgrip strength (P ≥ 0.05; Table  4). Within 
stratified analyses, no differences in results between men 
and women were observed (Online resource 2, Supplemen-
tary Table 1).
Discussion
To our knowledge, this is the first study investigating the 
associations of CT-derived muscle and adipose tissue 
parameters with long-term HRQoL in stage I–III CRC 
Table 1  Socio-demographic 
and clinical characteristics of 
participants included in the 
current analyses, participants 
without computed tomography 
(CT) image data, and non-
participants of the cross-
sectional part of the EnCoRe 
study
NA not available, SD standard deviation
a Data missing for 16 survivors (6 participants included in analyses, 2 participants without CT image data, 
and 8 non-participants)
Characteristic Included in analyses 
(n = 104)
No available CT image 




Age at diagnosis (years), mean (SD) 64.3 (9.0) 64.6 (9.2) 67.8 (11.9)
Gender, n (%)
 Men 62 (59.6) 34 (66.7) 127 (58.3)
 Women 42 (40.4) 17 (33.3) 91 (41.7)
Years since diagnosis, mean (SD) 5.2 (1.7) 6.7 (1.7) 5.7 (1.7)
Tumor subsite, n (%)
 Colon 60 (57.7) 23 (45.1) 132 (60.6)
 Rectosigmoid 2 (1.9) 5 (9.8) 8 (3.7)
 Rectum 42 (40.4) 23 (45.1) 78 (35.8)
Tumor  stagea, n (%)
 I 27 (27.6) 16 (32.7) 55 (26.2)
 II 33 (33.7) 21 (42.9) 81 (38.6)
 III 38 (38.8) 12 (24.5) 74 (35.2)
Treatment with chemotherapy, n (%) 59 (56.7) 21 (41.2) 95 (43.6)
Treatment with radiotherapy, n (%) 38 (36.5) 22 (43.1) 66 (30.3)
Education level, n (%)
 Low 29 (27.9) 8 (17.0) NA
 Medium 31 (29.8) 21 (44.7)
 High 44 (42.3) 18 (38.3)
Number of comorbid conditions, n (%)
 None 29 (27.9) 8 (16.0) NA
 1 30 (28.8) 8 (16.0)
 ≥2 45 (45.3) 34 (68.0)
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Table 4  Mean differences in long-term maximum handgrip strength 
in colorectal cancer survivors according to tertiles of area of visceral 
and intermuscular adipose tissue, mean muscle attenuation, and skel-
etal muscle index (SMI) at colorectal cancer diagnosis
P values in italic indicate a significant level of P < 0.05
CI confidence interval, HU Hounsfield units, MD mean difference, 
Ref reference category, SD standard deviation, SMI skeletal muscle 
index
Adjusted for: gender, age at diagnosis (years), body mass index at 
health-related quality of life assessment (kg/m2), number of comor-
bidities (0/1/2+), cancer stage (I/II/III), and chemotherapy treatment 
(yes/no)
a With gender-specific tertiles for visceral adipose tissue (men: T1, 
≤100.3; T2, 102.7–196.5; T3, ≥199.2; women: T1, ≤58.7; T2, 59.2–
131.0; T3, ≥139.1  cm2), intermuscular adipose tissue (men: T1, ≤8.3; 
T2, 8.8–14.2; T3, ≥14.3; women: T1, ≤9.6; T2, 9.7–17.8; T3, ≥17.9 
 cm2), and SMI (men: T1, ≤48.6; T2, 48.8–53.8; T3, ≥54.0; women: 
T1, ≤38.7; T2, 38.7–43.9; T3, ≥44.3  cm2/m2), and overall tertiles for 
muscle attenuation (T1, ≤33.6; T2, 33.6–41.6; T3, ≥42.0 Hounsfield 
units)
b Dichotomized based on published cutoff for visceral adipose tissue 
area [46]
c Dichotomized based on cutoff [31]; data missing for 9 participants 




Visceral adipose tissue  (cm2, n = 98)a
 T1 Ref
 T2 1.9 −1.7, 5.4
 T3 2.9 −1.6, 7.4
 Ptrend 0.20
 Per SD increase 1.5 −0.5, 3.4
 Visceral  obesityb 3.9 0.7, 7.2
Intermuscular adipose tissue  (cm2, n = 96)a
 T1 Ref
 T2 0.4 −3.0, 3.7
 T3 −1.7 −5.5, 2.2
 Ptrend 0.42
 Per SD increase −0.6 −2.4, 1.2
Muscle attenuation (HU, n = 96)a
 T1 Ref
 T2 1.7 −2.0, 5.4
 T3 2.0 −1.9, 6.0
 Ptrend 0.33
 Per SD increase 1.2 −0.5, 2.9
SMI  (cm2/m2, n = 96)a
 T1 Ref
 T2 1.3 −2.1, 4.7
 T3 −0.5 −4.4, 3.4
 Ptrend 0.83
 Per SD increase 1.0 −1.0, 3.0
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survivors, 2–10 years post-diagnosis. In contrast to our 
prior hypotheses, we observed no statistically significant 
associations of visceral adiposity, muscle fat infiltration, 
and muscle mass at CRC diagnosis with investigated 
long-term HRQoL outcomes. In addition, even though we 
observed that a substantial proportion of CRC survivors 
were classified as viscerally obese and sarcopenic at CRC 
diagnosis, we did not observe significant associations of 
these unfavorable body composition profiles with long-
term HRQoL. All observed mean differences were below 
predefined minimal important differences, indicating that 
the differences observed are small and not likely to be 
clinically relevant.
Our results suggest that an unhealthy body composi-
tion at CRC diagnosis might not be an important deter-
minant of long-term HRQoL in CRC survivors. Although 
increased visceral adiposity and muscle wasting may 
negatively affect clinical outcomes and functioning of 
CRC patients shortly after diagnosis and treatment [19], 
long-term CRC survivors may recover in terms of func-
tioning and HRQoL. Prospective studies are needed to 
study associations of body composition at CRC diagnosis 
with short- and long-term HRQoL and test this hypoth-
esis. Statistical power may have been limited for detect-
ing real associations due to our relatively small sample 
size, but all observed mean differences in HRQoL out-
comes were smaller than predefined minimal important 
differences. This indicates that observed associations of 
body composition parameters with HRQoL were not clin-
ically relevant in our sample of long-term CRC survivors. 
Furthermore, recovery of functioning in the longer term 
was confirmed by our data, as we observed no significant 
associations of these body composition parameters at 
diagnosis with maximum handgrip strength (a measure of 
muscle strength and function) 2–10 years post-diagnosis. 
Thus, instead of their body composition at CRC diagno-
sis, other characteristics, such as comorbidities and level 
of physical activity during CRC survivorship, could be 
more relevant determinants of HRQoL in CRC survivors 
[8, 70]. It is important to note, however, that our study 
population did not include stage IV CRC survivors who 
have a worse prognosis. A previous study in a small sam-
ple of 50 stage IV CRC patients observed significant 
cross-sectional associations of CT-derived sarcopenia at 
referral for potential chemotherapy treatment (time since 
diagnosis not reported) with physical functioning, but not 
with other HRQoL outcomes [38]. We did not observe 
a significant association of sarcopenia at CRC diagnosis 
with physical functioning or any other HRQoL outcome. 
This difference is likely due to differences between this 
previous study and our study, as stage IV CRC patients 
were not included and measurements were conducted at 
different time points in our study (CT scans at diagnosis 
and HRQoL ≥2 years post-diagnosis).
Comparison of our results with findings from previous 
studies in CRC patients is complicated by heterogene-
ity in methods of CT image analyses used (e.g., analysis 
level and/or software), and by differences between study 
populations (e.g., stage and ethnicity). A previous study 
in US [71] stage I–IV rectal cancer patients reported a 
mean visceral adipose tissue area of 108.0  cm2, assessed 
through analysis of CT images at the level of the umbilicus 
(L3–L4). This is lower than the mean value we observed 
(136.1  cm2), which is likely due to differences between 
study populations. Previous studies in CRC patients have 
observed a large range in prevalence of visceral obesity of 
17.5–61.4%, using a variety of CT-based analysis protocols 
and cutoffs [19]. We applied recently published threshold 
values for CT-based analysis of visceral adipose tissue area 
at the level of L3–L4 in gastrointestinal cancer (including 
CRC) patients [46], and observed a prevalence of 47% in 
our study population. For SMI and muscle attenuation, 
our results (mean SMI 51.3  cm2/m2 in men, 42.6  cm2/m2 
in women; muscle attenuation: 37.8 HU in men, 36.2 HU 
in women) are comparable with averages reported in pre-
vious studies in stage I–IV CRC patients with analysis of 
CT images at L3 (range in mean SMI: 51.5–57.5  cm2/m2 
in men, and 40.7–46.5 cm2/m2 in women [25, 27, 28, 31]; 
and mean muscle attenuation of 35.5 HU in men, and 36.2 
HU in women [31]). Similarly, the proportion of sarco-
penic patients at CRC diagnosis we observed in our sam-
ple (32%) falls within the range reported in previous studies 
using CT-based analysis at the level of L3 (25–48%) [25, 
28, 29, 31].
An important strength of our study was the use of CT 
image analyses, which enabled us to accurately and pre-
cisely determine adipose and muscle tissue at CRC diagno-
sis. As parameters of muscle wasting, we determined SMI 
as a measure for muscle mass, and mean muscle attenua-
tion and intermuscular adipose tissue area as measures for 
muscle fat infiltration and quality. Low correlations of the 
latter parameters with SMI in our study population indicate 
that these measure distinct features of the muscle wast-
ing process (both r = 0.0). CT-based analysis is regarded 
superior to anthropometric measures of body composition 
including BMI, which cannot differentiate between differ-
ent types of body tissues [18]. Correlations between BMI 
at CRC diagnosis with CT-derived parameters of body 
composition were low to moderate in our study, illustrat-
ing the differences between BMI and these measures. By 
retrospective analysis of CT images from CRC survivors in 
our cross-sectional sample, we were able to study longitu-
dinal associations of body composition at CRC diagnosis 
with HRQoL, 2–10 years later. However, a limitation of our 
cross-sectional design is the possibility of selection bias. 
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Based on the differences observed between participants 
and non-participants, it is likely that survivors with a more 
unfavorable body composition at CRC diagnosis and lower 
long-term HRQoL were less likely to participate, which 
could have attenuated our associations. Another limita-
tion was that no CT images were available for a substantial 
proportion of CRC survivors, probably due to changes in 
diagnostic procedures over the years, which was supported 
by the observation that fewer CT images were available 
from CRC survivors diagnosed longer ago. We additionally 
observed that participants with available CT scans had less 
often ≥2 comorbidities that those without a CT scan, which 
also suggests that a more ‘healthy’ subset of CRC survivors 
was included in the current study. This could have further 
attenuated our findings. In addition, included CRC survi-
vors had a wide range in time since diagnosis (2–10 years), 
but we could not analyze the associations between body 
composition variables and HRQoL stratified for time since 
diagnosis due to our limited sample size. The occurrence of 
a response shift (i.e., change in internal standards, personal 
values, and the conceptualization of HRQoL due to the 
confrontation with a life-threatening disease such as cancer 
[72]) in the post-diagnosis period cannot be excluded and 
may have influenced our findings. Future prospective stud-
ies are needed in which CT scans are collected in a stand-
ardized way at CRC diagnosis in a consecutive sample of 
CRC patients, and survivors are followed up with repeated 
measurements of HRQoL. This will enable an investigation 
of the associations of body composition parameters at CRC 
diagnosis with the development of HRQoL during the CRC 
survivorship trajectory and will provide insight into the 
temporality of associations. Furthermore, we were unable 
to determine the presence of sarcopenic obesity at CRC 
diagnosis [30, 73], because data to determine BMI at CRC 
diagnosis were not available in a substantial proportion of 
participants (19%).
In conclusion, although parameters of increased visceral 
adiposity and excessive muscle wasting at CRC diagnosis 
have been associated with worse short-term clinical out-
comes and survival, our findings suggest that these param-
eters may not be associated with long-term HRQoL in our 
sample of stage I–III CRC survivors. This suggests that 
interventions targeting CRC patients with an unhealthy 
body composition at diagnosis could be favorable towards 
improving short-term clinical outcomes and survival, but 
might not be relevant for improving long-term HRQoL. 
Prospective studies are needed to further investigate longi-
tudinal associations of body composition at CRC diagnosis 
with HRQoL in CRC survivors. Since we found that mus-
cle wasting and visceral adiposity were relatively common 
in our population of included stage I–III CRC patients, we 
think it is important that interventions are being devel-
oped and tested to reduce visceral adiposity and inhibit 
muscle wasting in CRC patients. Studying the effects of 
these interventions on short- and long-term HRQoL and 
other relevant outcomes, preferably in randomized con-
trolled trials, will provide more insight into the potential 
causality of associations of muscle wasting and visceral 
adiposity with short- and long-term health and well-being 
of CRC survivors.
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